JP2020506685A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506685A5
JP2020506685A5 JP2019538439A JP2019538439A JP2020506685A5 JP 2020506685 A5 JP2020506685 A5 JP 2020506685A5 JP 2019538439 A JP2019538439 A JP 2019538439A JP 2019538439 A JP2019538439 A JP 2019538439A JP 2020506685 A5 JP2020506685 A5 JP 2020506685A5
Authority
JP
Japan
Prior art keywords
antibody molecule
amino acid
seq
acid sequence
sulfatase motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506685A (ja
JP7303110B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/014224 external-priority patent/WO2018136626A1/en
Publication of JP2020506685A publication Critical patent/JP2020506685A/ja
Publication of JP2020506685A5 publication Critical patent/JP2020506685A5/ja
Priority to JP2023029602A priority Critical patent/JP2023065550A/ja
Application granted granted Critical
Publication of JP7303110B2 publication Critical patent/JP7303110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538439A 2017-01-18 2018-01-18 抗体分子－薬物コンジュゲートおよびその使用 Active JP7303110B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023029602A JP2023065550A (ja) 2017-01-18 2023-02-28 抗体分子－薬物コンジュゲートおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762447813P 2017-01-18 2017-01-18
US62/447,813 2017-01-18
US201762492641P 2017-05-01 2017-05-01
US62/492,641 2017-05-01
PCT/US2018/014224 WO2018136626A1 (en) 2017-01-18 2018-01-18 Antibody molecule-drug conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023029602A Division JP2023065550A (ja) 2017-01-18 2023-02-28 抗体分子－薬物コンジュゲートおよびその使用

Publications (3)

Publication Number Publication Date
JP2020506685A JP2020506685A (ja) 2020-03-05
JP2020506685A5 true JP2020506685A5 (enExample) 2021-02-25
JP7303110B2 JP7303110B2 (ja) 2023-07-04

Family

ID=61148525

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538439A Active JP7303110B2 (ja) 2017-01-18 2018-01-18 抗体分子－薬物コンジュゲートおよびその使用
JP2023029602A Withdrawn JP2023065550A (ja) 2017-01-18 2023-02-28 抗体分子－薬物コンジュゲートおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023029602A Withdrawn JP2023065550A (ja) 2017-01-18 2023-02-28 抗体分子－薬物コンジュゲートおよびその使用

Country Status (9)

Country Link
US (1) US11890319B2 (enExample)
EP (1) EP3571223B1 (enExample)
JP (2) JP7303110B2 (enExample)
KR (1) KR102697723B1 (enExample)
CN (1) CN110431150A (enExample)
AU (1) AU2018209940A1 (enExample)
CA (1) CA3049449A1 (enExample)
ES (1) ES2994374T3 (enExample)
WO (1) WO2018136626A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
AU2019406452B2 (en) 2018-12-21 2021-09-16 Ose Immunotherapeutics Humanized anti-human-PD-1 antibody
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3947689A4 (en) * 2019-03-27 2023-03-29 National Research Council of Canada ANTIGEN BINDING AGENTS SPECIFIC TO BINDING THE RECEPTOR VARIANT III OF THE EPIDERMAL GROWTH FACTOR
US12643944B2 (en) 2019-11-12 2026-06-02 Iprogen Biotech Inc. Antibody-payload conjugates with enhanced delivery domain and uses thereof
JP7479135B2 (ja) * 2019-11-12 2024-05-08 デンカ株式会社 抗ｒｓウイルスを認識する抗体、並びに該抗体を用いた免疫測定方法及び免疫測定器具
CN115427448A (zh) * 2020-01-10 2022-12-02 达因疗法公司 肌肉靶向复合物及其用途
KR20240085798A (ko) * 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
AU2021293287A1 (en) * 2020-06-18 2023-02-16 Nextcure, Inc. Compositions and methods for modulating FLRT3 mediated signal transduction
CA3251953A1 (en) * 2022-06-09 2023-12-14 Santa Ana Bio, Inc. C-KIT AND/OR SIGLEC TARGETING ANTIBODIES AND THEIR USES
WO2025160291A1 (en) * 2024-01-23 2025-07-31 Lahjavida, Inc. Prodrugs based on tumor targeting near infrared dye-drug conjugates (ddc)

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0233289B1 (en) 1984-12-26 1993-03-10 Teijin Limited Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody
IL81370A (en) 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
AU1807188A (en) 1987-04-10 1988-11-04 Xoma Corporation Human monoclonal antibodies binding determinants of gram negative bacteria
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
WO1990003186A1 (en) 1988-09-19 1990-04-05 Cetus Corporation Gram-negative bacterial endotoxin blocking monoclonal antibodies
US5221732A (en) 1988-12-06 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial magainin modified peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JPH04211393A (ja) 1990-02-08 1992-08-03 Sumitomo Pharmaceut Co Ltd ヒトモノクローナル抗体及びそれを有効成分とする緑膿菌感染症治療剤
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2042448A1 (en) 1990-06-05 1991-12-06 Jonathan P. Duvick Antimicrobial peptides and plant disease resistance based thereon
US5447914A (en) 1990-06-21 1995-09-05 Emory University Antimicrobial peptides
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
AU648140B2 (en) 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
GB9105292D0 (en) 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5607914A (en) 1993-01-13 1997-03-04 Pioneer Hi-Bred International, Inc. Synthetic antimicrobial peptides
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
US5734015A (en) 1995-06-19 1998-03-31 Magainin Pharmaceuticals Inc. Family of linear antimicrobial peptides from hagfish intestine
DE69637731D1 (de) 1995-08-23 2008-12-11 Univ British Columbia Antimikrobielle kationische peptide und methoden zu ihrer identifizierung
EP0866864A2 (en) 1995-12-13 1998-09-30 Zeneca Limited Antifungal proteins
US5714577A (en) 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US5994308A (en) 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US5773696A (en) 1996-03-29 1998-06-30 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
US5856127A (en) 1996-07-26 1999-01-05 The Research Foundation Of State University Of New York Antimicrobial peptides
WO1998007833A1 (en) 1996-08-22 1998-02-26 The Trustees Of The University Of Pennsylvania Compositions and methods for use of defensin
US6121436A (en) 1996-12-13 2000-09-19 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
US6307018B1 (en) 1996-12-24 2001-10-23 The Scripps Research Institute General chemical ligation
US5998374A (en) 1997-02-28 1999-12-07 The Regents Of University Of California Clavaspirins
NL1006164C2 (nl) 1997-05-29 1998-12-01 Univ Leiden Antimicrobiële peptiden.
FR2766191B1 (fr) 1997-07-21 2000-11-10 Ifremer Peptides anti-microbiens de crustaces
CA2298101A1 (en) 1997-07-31 1999-02-11 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
US6576755B1 (en) 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
WO1999015548A2 (en) 1997-09-25 1999-04-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Isolated and recombinant antimicrobial peptides thrombocidin-1 (tc-1) and thrombocidin-2 (tc-2) or variants thereof
NL1008139C2 (nl) 1998-01-27 1999-07-28 Stichting Tech Wetenschapp Antimicrobiële peptiden.
AU2683699A (en) 1998-02-18 1999-09-06 Harbor-Ucla Research And Education Institute Antimicrobial peptides and derived metapeptides
US6476189B1 (en) 1998-08-12 2002-11-05 National Institute Of Agrobiological Sciences Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
ATE332306T1 (de) 1998-08-31 2006-07-15 Gryphon Therapeutics Inc Chemische anknüpfung unter einbeziehung von einer lipid-matrix und herstellung von membranpolypeptiden
US20040052814A1 (en) 1998-09-28 2004-03-18 Wenyuan Shi Fusion proteins for targeted delivery of antimicrobial peptides
US6107460A (en) 1999-03-01 2000-08-22 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use thereof
US7244710B2 (en) 2002-05-21 2007-07-17 Zengen, Inc. Treatment of ophthalmic infections using antimicrobial peptides
BR0009947A (pt) 1999-04-23 2002-12-31 St Jude Medical Conjugado antimicrobiano, método de eliminar microorganismos viáveis, dispositivo médico, e, método de formar um conjugado antimicrobiano
EP1179012B2 (en) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
FR2796072B1 (fr) 1999-07-08 2003-09-19 Centre Nat Rech Scient Peptides anti-microbiens de mollusques
US7071293B1 (en) 1999-08-18 2006-07-04 The University Of Iowa Research Foundation Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt
US20030143234A1 (en) 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
EP1101771A1 (en) 1999-11-15 2001-05-23 Korea Kumho Petrochemical Co. Ltd. Pathogen-induced genes from Capsicum annuum
US6573361B1 (en) 1999-12-06 2003-06-03 Monsanto Technology Llc Antifungal proteins and methods for their use
IL150224A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
EP1130091A3 (en) 2000-03-01 2001-11-14 Message Pharmaceuticals, Inc. Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
US6570040B2 (en) 2000-03-16 2003-05-27 The Regents Of The University Of California Chemoselective ligation
US6337317B1 (en) 2000-06-27 2002-01-08 The University Of British Columbia Antimicrobial peptides and methods of use thereof
US6492328B2 (en) 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
WO2002009738A1 (en) 2000-07-28 2002-02-07 Murphy Christopher J Transplant media
EP1319025A2 (en) * 2000-09-07 2003-06-18 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
US6875907B2 (en) 2000-09-13 2005-04-05 Pioneer Hi-Bred International, Inc. Antimicrobial peptides and methods of use
GB0026924D0 (en) 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
US6887847B2 (en) 2001-02-16 2005-05-03 University Of Pittsburgh Virus derived antimicrobial peptides
US7314858B2 (en) 2001-04-18 2008-01-01 The Regents Of The University Of California Retrocyclins: antiviral and antimicrobial peptides
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
US6790833B2 (en) 2001-08-08 2004-09-14 The Research Foundation Of The State University Of New York Antifungal and antibacterial agents
US6743598B2 (en) 2001-08-10 2004-06-01 Mycologics, Inc. Methods for the identification of fungal glucose utilization inhibitors and antifungal agents
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US7001924B2 (en) 2001-09-21 2006-02-21 Message Pharmaceuticals Inhibitors of RNase P proteins as antibacterial compounds
US6478825B1 (en) 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US7091185B2 (en) 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
ATE458006T1 (de) 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
EP1706425A2 (en) 2003-12-05 2006-10-04 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
JP2005179268A (ja) 2003-12-19 2005-07-07 Gc Corp 口腔用組成物
EP1690875A1 (en) 2005-02-14 2006-08-16 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2009120611A2 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
KR20120016086A (ko) 2009-04-09 2012-02-22 켄타 바이오테크 아게 슈도모나스 애루지노사 혈청형 ｉａｔｓ ０１의 지질다당류(ｌｐｓ) 특이적 인간 단일클론 항체
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
JP2013521758A (ja) 2010-02-18 2013-06-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 緑膿菌の血清型ａ型リポ多糖に対する抗体
KR101367832B1 (ko) 2010-04-21 2014-02-27 건국대학교 산학협력단 종양 억제 타겟으로서 Ｈａｄｅｓ의 용도
EP2659273A4 (en) 2010-12-29 2015-07-01 Alper Biotech Llc MONOCLONAL ANTIBODIES TO ALPHA-ACTININ-4-ANTIGENS AND THEIR USE
EP2663647A4 (en) * 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
CA3149018A1 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013024905A1 (en) 2011-08-16 2013-02-21 Meiji Seika Pharma Co., Ltd. Combination drug of antibody against lipopolysaccharide of pseudomonas aeruginosa and antibacterial agent
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9556228B2 (en) * 2011-09-22 2017-01-31 Universitaet Leipzig Modified apidaecin derivatives as antibiotic peptides
US9428575B2 (en) 2012-12-31 2016-08-30 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018136626A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
JP6970090B2 (ja) Ｃ末端リジンで結合体化された免疫グロブリン
KR101990341B1 (ko) 세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
JP7514836B2 (ja) トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
BR112015023589B1 (pt) Método para a produção de um conjugado de imunoligante/carga útil
JPWO2018199337A1 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2018509394A5 (enExample)
JP2019525897A (ja) リジン結合体化免疫グロブリン
JP2000512633A (ja) チオエーテル結合を含む環状ポリペプチドおよびそれらの調製方法
WO2007079755A1 (en) Reimmunization and antibody design
CN110431150A (zh) 抗体分子-药物偶联物及其用途
JP2024507540A5 (enExample)
JP2003522117A (ja) 治療薬の送達のための二機能性分子
KR102861586B1 (ko) 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
US20180028682A1 (en) Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
EP1015493A1 (en) Novel epithelial tissue targeting agent
WO2014044793A2 (en) Cd22-binding peptides
US11020490B2 (en) Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit
EA045916B1 (ru) Антитело, содержащее глутаминсодержащее с-концевое удлинение легкой цепи, его конъюгаты, способы и пути применения
JP2010504313A (ja) ペプチド
HK1217296B (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme